The US non-profit organization the Institute for Clinical and Economic Review (ICER) has released a new report which finds little evidence to demonstrate that abuse-deterrent opioids have an impact on opioid abuse.
The report comes as America grapples with an epidemic of opioid abuse, thought to be fuelled by the use of prescription painkillers, which analysts estimate is claiming the lives of over 30,000 people per year.
The researchers assessed the comparative clinical effectiveness and value of ten abuse-deterrent formulations of opioids, and conclude that: “Evidence was insufficient to determine a net health benefit, given uncertainties regarding the balance between reductions in abuse and transition to abuse of heroin and other opioids.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze